Clinical Trial Update: Plasma Levels of Vascular Endothelial Growth Factor Before and After Intravitreal Injection of Aflibercept [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating plasma VEGF levels before and after intravitreal aflibercept injection in exudative age-related macular degeneration.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Exudative Age-related Macular Degeneration

Drugs mentioned

• Aflibercept (Aflibercept)

Snippet

Sponsor: Oslo University Hospital | Conditions: Exudative Age-related Macular Degeneration | Phase 4 | Status: COMPLETED